Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.

ABSTRACT:

Background

We aimed to compare the efficacy of tocilizumab with conventional immunotherapy in refractory patients with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG).

Methods

This single-center prospective cohort study was based on patients from an MG registry study in China and conducted from February 10, 2021 to March 31, 2022. Adult refractory patients with AChR-Ab+ gMG were assigned to tocilizumab or conventional immunotherapy groups. The primary efficacy outcome was the mean difference of MG activities of daily living (MG-ADL) change at weeks 4, 8, 12, 16, 20, 24 corresponding to that at the baseline between the two groups. A generalized estimating equation model was used for the primary outcome analysis. Safety was assessed base

SUBMITTER: Ruan Z 

PROVIDER: S-EPMC11187874 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature